MK-0677 raises IGF-I and cortisol only via intact pituitary, not direct organ action
Background
Growth hormone secretagogues such as MK-0677 (ibutamoren) were developed to stimulate the GHSR (ghrelin receptor) and drive pulsatile GH release from the anterior pituitary, with downstream elevation of IGF-I serving as the primary anabolic endpoint. A key mechanistic ambiguity had persisted: because MK-0677 circulates systemically after oral dosing, it could theoretically stimulate IGF-I production directly at the liver or drive cortisol secretion directly at the adrenal cortex, bypassing the hypothalamic-pituitary axis entirely. Resolving this distinction matters clinically because a direct hepatic or adrenal action would change safety profiling, dosing logic, and the interpretation of IGF-I as a surrogate biomarker of pituitary engagement. This study used a surgically ablated pituitary model to isolate pituitary-dependent from pituitary-independent hormonal responses.
Study Design
Beagle dogs received MK-0677 1 mg/kg orally as a pre-surgical baseline challenge to establish individual GH, IGF-I, and cortisol responses. Animals then underwent hypophysectomy (hypox; n = 7) or sham surgery (sham; n = 5). Six days post-surgery, MK-0677 was re-administered and hormonal responses were re-evaluated using serum ELISA-type measurements. To confirm residual axis responsiveness, each dog was treated with porcine GH (PST 0.1 IU/kg s.c.) to probe the GH-IGF-I axis, and hypox dogs received ACTH GEL 2.2 U/kg i.m. to confirm adrenal cortex functional integrity.
Results
Before surgery, peak GH responses to MK-0677 were comparable across groups: 83.7 ± 19.2 ng/ml (pre-sham), 108 ± 26.2 ng/ml (post-sham), and 121.2 ± 13.6 ng/ml (pre-hypox), with no statistically significant differences. After hypophysectomy, MK-0677 produced a mean peak GH of only 2.3 ± 0.7 ng/ml, confirming successful ablation. Pre-surgical IGF-I rose to 243 ± 27 ng/ml (sham group) and 224 ± 47 ng/ml (hypox group) after MK-0677; surgery caused a ≥50% drop in baseline IGF-I across both groups. Post-surgically, sham dogs showed IGF-I rising from 78 ± 14 to 187 ± 31 ng/ml after MK-0677, while hypox dogs remained flat at 17.7 ± 2.4 ng/ml. PST restored IGF-I in hypox dogs from 17.7 ± 2.4 to 199 ± 41 ng/ml, confirming intact hepatic responsiveness to exogenous GH.
IGF-I levels in hypophysectomized dogs given MK-0677 remained unchanged at 17.7 ± 2.4 ng/ml, versus a rise from 78 ± 14 to 187 ± 31 ng/ml in sham controls — direct liver stimulation is ruled out.
Cortisol increased 3.7-fold (pre-sham), 3.6-fold (post-sham), and 3.6-fold (pre-hypox) following MK-0677 but showed zero increase in post-hypox dogs, despite ACTH GEL restoring cortisol to physiological levels in those same animals, confirming intact adrenal function.
Key Findings
- IGF-I unchanged at 17.7 ± 2.4 ng/ml in hypox dogs after MK-0677; sham dogs rose from 78 ± 14 to 187 ± 31 ng/ml
- Peak GH after MK-0677 collapsed from 121.2 ± 13.6 ng/ml (pre-hypox) to 2.3 ± 0.7 ng/ml (post-hypox)
- Cortisol increased 3.6–3.7-fold with MK-0677 in intact dogs; zero increase in hypophysectomized dogs
- Exogenous PST restored IGF-I in hypox dogs from 17.7 ± 2.4 to 199 ± 41 ng/ml, confirming intact liver axis
- Surgery caused ≥50% drop in serum IGF-I levels in both sham and hypox groups
Why It Matters
MK-0677's entire hormonal efficacy — both IGF-I elevation and cortisol rise — is pituitary-gated, meaning any context that compromises hypothalamic-pituitary function (severe illness, pituitary adenoma, prior radiation, hypopituitarism) would be expected to blunt or abolish its downstream benefits. For clinicians and informed users, IGF-I response is a valid biomarker of pituitary engagement rather than a confounded readout of direct hepatic stimulation. Protocol designers can rely on IGF-I monitoring to confirm true axis activation and not mistake a flat IGF-I response for a dosing failure when the pituitary itself is the limiting variable. The finding also clarifies that cortisol elevation on MK-0677 is ACTH-mediated, not adrenal-direct, which is relevant for interpreting adrenal stress responses during supplementation.
TitrateLab articles covering MK-677
Written by TitrateLab, separately from the study summarized above.
